Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial

Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial

Bibliografske podrobnosti
Main Authors:	Folegatti, PM, Harrison, K, Lopez, KR, Tilley, MW, Lopez-Camacho, C, Kim, YC, Preciado-Llanes, L, Rossi, SL, Poulton, I, Jenkin, D, Datoo, M, Themistocleous, Y, Lawrie, A, Roberts, R, Ewer, K, Berrie, E, Hill, A, Reyes-Sandoval, A
Format:	Conference item
Jezik:	English
Izdano:	American Society of Tropical Medicine and Hygiene 2019

Podobne knjige/članki

NEUTRALIZING ANTIBODY TITERS TO SIMIAN ADENOVIRAL VECTORS FOLLOWING ADCH63 ME-TRAP IMMUNIZATION IN HUMANS
od: Goodman, A, et al.
Izdano: (2009)

A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial
od: Folegatti, P, et al.
Izdano: (2021)

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
od: Folegatti, PM, et al.
Izdano: (2020)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
od: Folegatti, P, et al.
Izdano: (2019)

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
od: Pedro M. Folegatti, et al.
Izdano: (2021-07-01)

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
od: Fitzgerald, J, et al.
Izdano: (2003)

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
od: Folegatti, PM, et al.
Izdano: (2020)

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.
od: Reyes-Sandoval, A, et al.
Izdano: (2008)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
od: Pedro M. Folegatti, et al.
Izdano: (2019-05-01)

Correction: Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
od: Reyes-Sandoval, A, et al.
Izdano: (2011)

Immunogenicity of a pre-erythrocytic-stage malaria insert ME-trap encoded by novel simian adenoviral vectors
od: Reyes-Sandoval, A, et al.
Izdano: (2005)

EVALUATION OF SIMIAN ADENOVIRAL VECTOR ADCH63 EXPRESSING MSP-1 AS A CANDIDATE BLOOD-STAGE MALARIA VACCINE
od: Goodman, A, et al.
Izdano: (2009)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
od: O'Hara, G, et al.
Izdano: (2012)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
od: Ewer (nee Russell), K, et al.
Izdano: (2017)

The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes
od: von Delft, A, et al.
Izdano: (2017)

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.
od: Reyes-Sandoval, A, et al.
Izdano: (2004)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
od: Katie Ewer, et al.
Izdano: (2017-12-01)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
od: Capone, S, et al.
Izdano: (2010)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
od: Capone, S, et al.
Izdano: (2010)

Safety and immunogenicity of ChAdOx1 MERS Vaccine Candidate in Healthy Middle Eastern Adults: a dose-escalation, open-label, non-randomised, phase 1b trial
od: Bosaeed, M, et al.
Izdano: (2021)

Simian adenoviruses as vaccine vectors
od: Morris, S, et al.
Izdano: (2016)

Simian adenoviruses as vaccine vectors
od: Morris, S, et al.
Izdano: (2016)

A single and un-adjuvanted dose of a chimpanzee adenovirus-vectored vaccine against chikungunya virus fully protects mice from lethal disease
od: Campos, R, et al.
Izdano: (2019)

Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults
od: Coughlan, L, et al.
Izdano: (2018)

Safety and immunogenicity of adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies
od: Folegatti, P, et al.
Izdano: (2021)

Simian malaria in Brazil
od: Leonidas M. Deane
Izdano: (1992-01-01)

Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults
od: L. Coughlan, et al.
Izdano: (2018-03-01)

Divergent Simian Arteriviruses Cause Simian Hemorrhagic Fever of Differing Severities in Macaques
od: Victoria Wahl-Jensen, et al.
Izdano: (2016-03-01)

Adenoviral Keratoconjunctivitis
od: Alexander Bialasiewicz
Izdano: (2007-04-01)

Quantifying Adenoviral Titers by Spectrophotometry
od: S.J. O’Carroll, et al.
Izdano: (2000-03-01)

Considerations for Developing Robot-Assisted Crisis De-Escalation Practices
od: Kathryn Pierce, et al.
Izdano: (2023-03-01)

Editorial: Adenoviral Infection and Immunity, and Adenoviral Vectors for Gene Therapy Applications
od: Qiwei Zhang, et al.
Izdano: (2022-03-01)

Simian virus 40 and cancer
od: Sandra Eliasz, et al.
Izdano: (2011-12-01)

Simian virus 40 and cancer
od: Sandra Eliasz, et al.
Izdano: (2011-12-01)

Simian virus 40 in humans
od: Tognon Mauro, et al.
Izdano: (2007-07-01)

Censorship, or the Wisdom of the Simian Trinity
od: Rupendra Guha-Majumdar
Izdano: (2018-11-01)

New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.
od: Goodman, A, et al.
Izdano: (2010)

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya [version 1; peer review: 2 approved]
od: Omar Ngoto, et al.
Izdano: (2023-10-01)

A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease
od: Rafael Kroon Campos, et al.
Izdano: (2019-11-01)

Simian Foamy Virus Co-Infections
od: Shannon M. Murray, et al.
Izdano: (2019-09-01)